SUPPLEMENTARY DATA

Figure S1.

No differences were observed in IL-12 and IL-23 serum levels between cases and controls, whereas IL-22 levels were significantly increased in cases (n=227 cases and 55 controls). All values expressed as mean ± S.E.M. Statistical significance indicated by one symbol ($p<0.05$), 2-tailed t-test.

Figure S2.

No difference was observed in serum IL-22 levels between risk carriers and non-risk carriers (n=202 affected homozygous risk allele carriers, n=17 affected non-carriers).

Figure S3.

The heatmap shows the 30 genes with the highest fold change in lesional skin from *IL12B* risk allele positive individuals carrying the rs3212227 A allele and increased overlap with genes induced by IFN-γ, whereas there was decreased overlap with IL-17, IL-22 and TNF induced signatures.

Figure S4.

The heatmap shows the 30 genes with the highest fold change in lesional skin from *IL12B* risk allele positive individuals carrying the rs6887695 G allele and increased overlap with genes induced by IFN-γ, whereas there was decreased overlap with IL-17, IL-22 and TNF induced signatures.

Figure S5

Dose dependent and time course for the average fold change in expression of the *IL12A*, *IL12B*, *IL12A* and *IL1B.*

Supplementary Table 1.

Genotypes of patients for the *IL12B* SNPs used in microarray experiment.



Supplementary Figure 1



Supplementary Figure 2



Supplementary Figure 3



Supplementary Figure 4



Supplementary Figure 5